Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilnidipine crossover study in secondary Raynaud's syndrome
ACTRN12625000999437Phase 2Completed
- Sponsor
- Aisa Pharma, Inc.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cilnidipine in Raynaud disease (2 arms), sponsored by Aisa Pharma, Inc. Primary endpoint: Frequency of weekly Raynaud's phenomenon attacks. Started Mar 2023; status: completed.
02
Drugs
cilnidipine
03
Conditions
Raynaud disease
Beyond the preview
Go deeper on ACTRN12625000999437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000999437.